Table 4.

Univariate analysis for overall survival in 61 patients with triple negative breast cancer expressing BCL11A gene

Variables		BCL11A		BCL11A-XL		BCL11A-L		BCL11A-S
		OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Age > 50 years		0.5 (0.1–1.6)	0.22	0.7 (0.2–2.1)	0.51	0.4 (0.1–1.4)	0.14	0.3 (0.0–1.5)	0.13
Right site		2.7 (0.8–10.1)	0.13	1.1 (0.4–3.1)	0.91	1.4 (0.4–4.5)	0.61	6.8 (0.7–63.3)	0.09
Invasive ductal carcinoma (NST)		0.6 (0.2–2.1)	0.45	0.5 (0.2–1.69	0.27	0.2 (0.1–0.8)	0.02	0.2 (0.0–1.4)	0.11
Tumor size > 20 mm		0.9 (0.3–3.1)	0.90	0.7 (0.3–2.1)	0.56	0.6 (0.2–2.1)	0.46	1.3 (0.2–7.4)	0.74
Pathologic tumor classification	pT1	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	pT2	0.6 (0.2–2.2)	0.41	0.5 (0.2–1.7)	0.28	0.7 (0.2–2.5)	0.57	1.4 (0.2–9.6)	0.72
	pT3	–	–	–	–	–	–	–	–
	pT4	–	–	–	–	–	–	–
Regional lymph nodes involvement	pN0	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	pN1	1.3 (0.4–4.9)	0.69	0.7 (0.2–2.6)	0.63	1.1 (0.3–4.0)	0.94	1.5 (0.3–8.7)	0.65
	pN2	0.6 (0.1–5.7)	0.64	0.6 (0.1–3.9)	0.61	0.4 (0.0–4.6)	0.49	–	–
	pN3	–	–	–	–	–	–	–	–
Histologic grade	G1	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	G2	0.07 (0.003–1.73)	0.11	0.5 (0.03–8.0)	0.62	0.3 (0.0–4.9)	0.40	–	–
	G3	0.14 (0.01–1.70)	0.12	0.3 (0.02–3.0)	0.27	0.2 (0.0–2.3)	0.19	0.3 (0.02–4.12)	0.38
Tumor stage	I	Ref	Ref	Ref	Ref	Ref	Ref	–	–
	II	1.3 (0.3–5.8)	0.76	0.5 (0.1–2.1)	0.35	1.4 (0.3–7.1)	0.66	–	–
	III	0.30 (0.03–3.41)	0.33	0.2 (0.02–0.14)	0.07	0.2 (0.02–2.39)	0.20	–	–
Necrosis		0.7 (0.2–2.5)	0.56	0.4 (0.1–1.2)	0.11	0.6 (0.2–2.2)	0.43	1.0 (0.2–6.4)	0.97
Tumor infiltrating lymphocytes		1.1 (0.3–3.7)	0.94	1.0 (0.3–3.2)	0.96	1.3 (0.4–4.6)	0.67	5.0 (0.5–49.3)	0.17
Lymph vascular invasion		2.3 (0.6–9.2)	0.22	1.3 (0.4–4.5)	0.73	0.8 (0.2–3.5)	0.71	2.3 (0.3–16.5)	0.40
Ki 67 > 20		4.1 (0.5–34.9)	0.20	1.8 (0.4–7.7)	0.42	5.4 (0.6–47.0)	0.13	–	–
AR ≥ 10		0.1 (0.0–1.1)	0.07	0.3 (0.1–1.1)	0.06	0.2 (0.0–1.0)	0.05	–	–
High protein expression BCL11A		17.1 (4.0–72.2)	< 0.0001	16.4 (3.8–70.1)	< 0.0001	10.0 (2.4–41.9)	0.002	8.5 (1.3–54.8)	0.02